Skip to content
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
Shopping cart$0.00 0
Login
  • Home
  • About Us
  • Shop
    • Chinese innovative drug
    • Tablets
    • Capsules
    • Injection
    • oral solution
    • Cream/Gel/Ointment
    • ophthalmic preparations
    • Nasal preparations
    • Inhalation preparation
    • Implant
    • Chinese Medicine
  • Blog
  • Contact Us
Xpharma China
CARVYKTI (Ciltacabtagene Autoleucel)
  • Drug news

How much does CARVYKTI (Ciltacabtagene Autoleucel) Cost& price without insurance in China?

Ensacove (Ensartinib Hydrochloride Capsules)
  • Drug news

How much does Ensacove (Ensartinib Hydrochloride Capsules) Cost& price without insurance in China?

SOLIRIS (Eculizumab Injection)
  • Drug news

How much does SOLIRIS (Eculizumab Injection) Cost& price without insurance in China?

TEGLUTIK (Riluzole Oral Suspension)
  • Drug news

How much does TEGLUTIK (Riluzole Oral Suspension) Cost& price without insurance in China?

Taltz (Ixekizumab Injection)
  • Drug news

How much does Taltz (Ixekizumab Injection) Cost& price without insurance in China?

Kisqali (Ribociclib Tablets)
  • Drug news

How much does Kisqali (Ribociclib Tablets) Cost& price without insurance in China?

Highlightll
  • Approved News

Highlightll:Submitted an IPO application to the Hong Kong Stock Exchange.

GSK
  • Approved News

GSK :Nuvalent is being acquired for $10.6 billion.

everest medicines
  • Approved News

Everest Secures Exclusive Rights to Obinutuzumab Beta Across Key Asia-Pacific Markets

everest medicines
  • Approved News

Everest Secures Exclusive Rights to Sumecigrel (Vicagrel) Across Multiple Asia-Pacific Markets

zailab
  • Approved News

Zai Lab :TIVDAK®Tisotumab vedotinapproved for marketing in China.

Tasly
  • Approved News

Tasly :rhPro-UK Phase II Data for Pulmonary Embolism Released

Prev
1 … 3 4 5 6 7 8 9 … 22
Next
Contact us

WeChat: +86 139 2425 9988
WhatsApp : +852 9100 6363
Email: info@xpharma.com.cn

Rm F2-48, 6/F, No. 47 Guomao Road, Hainan, China

Useful Links
  • Medicines
  • Chinese innovative drug
  • Medicines Approved News
  • Drug Development News
  • Drug News
  • Privacy Policy
Email Newsletter

Subscribe to our newsletter and get 10% off your first purchase

Copyright © {2026} -Xpharma China